Drug Profile
Chlorin e6 - Apocare/Axios
Alternative Names: BLC-1013; Chlorin e6-polyvinylpyrrolidone; Fotolon; Photolon®; PhytochlorinLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator APOCARE Pharma
- Developer APOCARE Pharma; axios Pharma
- Class Antineoplastics
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- No development reported Bacterial infections
Most Recent Events
- 15 Feb 2018 Apocare completes phase-II clinical trials in Non-small cell lung cancer in Germany (IV) (EudraCT2013-001876-39)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Germany (IV)
- 09 Oct 2014 Phase-II clinical trials in Non-small cell lung cancer in Germany (IV) (EudraCT2013-001876-39)